Sun Pharma agrees to lower US drug prices under Trump plan; analysts see limited financial impact

Sun Pharmaceutical Industries will offer its drugs at prices matching other developed nations. This agreement aims to make healthcare affordable for low-income Americans. Analysts believe the financial impact on Sun Pharma will be minimal. The company’s US revenue contribution is significant, reinforcing its growth strategy. This pact recognizes Sun Pharma’s investment in the American market.

Breather for creditors: New NCLT bench stays the approval of a repayment plan proposed by Subhash Chandra

A special five-member NCLT bench stayed Subhash Chandra’s repayment plan approval. The tribunal also restrained the Essel Group founder from alienating any asset. This new bench stayed a smaller bench’s earlier order which had approved the plan. Dissenting creditors had sought protection against the guarantor’s asset alienation. The bench directed that the guarantor shall not…